Probing into low-density lipoprotein receptor-related protein (LPR)-1-independent peptide transcytosis mechanisms

在Borhane Annabi教授的指导下，quit<e:1> quemacei大学（UQAM）的分子肿瘤学实验室正在与AngioChem公司合作。AngioChem是一家总部位于蒙特利尔的公司，以其独特的合成策略而闻名，该策略适用于突破血脑屏障（BBB）的药物。这种技术将有助于更好地理解中枢神经系统和大脑相关疾病的分子和细胞过程。目前的项目将研究细胞内低密度脂蛋白受体相关蛋白(LRP)-1受体依赖和独立途径的分子机制。这些途径开辟了广泛的原始和复杂的分子策略，以探索血管生成和缺氧（低氧水平）对细胞和组织的影响等过程中涉及的新的和原始的分子和细胞过程。目前提出的合作项目旨在确定和研究可能参与血管内皮细胞运输的替代受体和/或相互作用的分子伙伴。这将增加对LRP-1转运机制的基本理解，这将使新的化学实体能够靶向关键的细胞过程，如那些涉及不受控制的致癌细胞增殖、细胞存活，以及那些涉及肿瘤相关血管生成和脑相关疾病的机制。预期的收益将有助于加拿大工业和UQAM，在上述联合研发活动中正在研究的目标领域有望利用突破性的平台技术，实现生物活性分子在血脑屏障上的生理运输。因此，AngioChem目前将自己定位为该领域的领导者。在学术上，UQAM的直接好处包括宝贵的培训机会，增加就业以及在蒙特利尔地区建立令人兴奋的工业合作伙伴关系。在科学方面，昆士兰大学的理学院将从这种积极的伙伴关系中获得极大的好处。

The Laboratory of Molecular Oncology at the Université du Québec à Montréal (UQAM) and under the direction of Professor Borhane Annabi is partnering with AngioChem a Montreal-based company reknown for its unique synthetic strategies applicable to breakthrough pharmacological agents that are optimized to cross the blood-brain barrier (BBB). Such technology will help to better understand molecular and cellular processes involved in central nervous system and brain-related disorders. The current project will investigate the molecular mechanisms involved in intracellular low-density lipoprotein receptor-related protein (LRP)-1 receptor-dependent and independent pathways. Such pathways open up a wide variety of original and sophisticated molecular strategies to explore new and original molecular and cellular processes involved in processes such as angiogenesis and impact of hypoxia (low oxygen levels) on cells and tissues. The current proposed collaborative project is designed to identify and investigate the alternate receptors and/or interacting molecular partners that could be involved in the transport of Angiopeps. This will result in an increased fundamental understanding of the LRP-1 transport mechanisms that will enable novel chemical entities to target critical cellular processes such as those involved in uncontrolled carcinogenic cell proliferation, cell survival, as well as those mechanisms involved in tumour-associated angiogenesis, and in brain-related disorders. The expected benefits will help to accrue to Canadian industry and to UQAM, the targeted areas under investigation in the described joint research and development activities are expected to leverage a breakthrough platform technology enabling physiological transport of bioactive molecules across the BBB. As such, AngioChem currently positions itself as the leader in this field. Academically, the direct benefits to UQAM include valuable training opportunities, increased employment as well as anchoring exciting industrial partnerships to the Montreal region. Scientifically, UQAM's Faculty of Sciences will enormously benefit of increased visibility from such an active partnership.